More To Go Or Is It Over? – Teva- Pharmaceutical Industries Ltd. ADR (TEVA)

Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) does about 9.60M shares in volume on a normal day but saw 7479764 shares change hands in Monday trading. The company now has a market cap of 19.08B USD. Its current market price is $16.85, marking an increase of 0.18% compared to the previous close of $16.82. The 52 week high reached by this stock is $17.39 whilst the lowest price level in 52 weeks is $7.27.

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has a 20-day trading average at $16.74 and the current price is -3.10% off the 52-week high compared with 131.77% distance from its 52-week low. The 50-day simple moving average of the closing price is $15.03 and its 200-day simple moving average is $11.85. If we look at the stock’s price movements over the week, volatility stands at 2.81%, which decreases to 2.77% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 61.24 to suggest the stock is neutral.

The consensus objective for the share price is $19.25, suggesting that the stock has a potential upside of 12.47% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 08, 2024 when JP Morgan upgraded the stock to “Neutral” and issued a price target of $14. Piper Sandler also upgraded the stock to “Overweight” from Neutral on February 12, 2024 at a price target of $12-$19. Jefferies upgraded its price target at $10-$14.

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stock is down -0.77% over the week and 5.31% over the past month. Its price is 61.40% year-to-date and 128.01% over the past year.

To reach the target analysts have set, the stock logically needs to grow 12.47 percent from here.

The company has a return on investment of -1.91% and return on equity of -6.08%. The forward price to earnings ratio is 6.13. The beta has a value of 0.91. Price to book ratio is 2.62 and price to sales ratio is 1.19.